When we talk about breakthroughs in cancer research, most focus on the moment of discovery: a new therapy, a promising trial result, or a headline-grabbing study.
When our hematological malignancy testing pilot project began in Eldoret, Kenya, there seemed to be a mismatch in relation to progress in healthcare. The region, like much of sub-Saharan Africa, had been focusing on combatting infectious diseases such as HIV and malaria—which was much-needed—yet cancer care was under-resourced.
